Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Axonics Modulation Technologies revenue
Axonics Modulation Technologies's revenue is $366.4 million.
What is Axonics Modulation Technologies's revenue?
- Axonics Modulation Technologies's revenue growth from 2017 to 2023 is 286,133.59%.
- Axonics Modulation Technologies has 416 employees, and the revenue per employee ratio is $880,718.
- Axonics Modulation Technologies's peak quarterly revenue was $116.2M in 2024(q3).
- Axonics Modulation Technologies peak revenue was $366.4M in 2023.
- Axonics Modulation Technologies annual revenue for 2022 was 273.7M, 51.81% growth from 2021.
- Axonics Modulation Technologies annual revenue for 2023 was 366.4M, 33.86% growth from 2022.
On this page
Zippi applies for you, and finds you a job.
Axonics Modulation Technologies historical revenue
Axonics Modulation Technologies's peak revenue was $366.4M in 2023. The peak quarterly revenue was $116.2M in 2024(q3).
Axonics Modulation Technologies's revenue increased from $128.0k in 2017 to $366.4M currently. That's a 286,133.59% change in annual revenue.
Axonics Modulation Technologies annual revenue
Axonics Modulation Technologies annual revenue over time
| Fiscal year / year | Axonics Modulation Technologies revenue |
|---|---|
| 2017 | $128,000 |
| 2018 | $707,000 |
| 2019 | $13.8M |
| 2020 | $111.5M |
| 2021 | $180.3M |
| 2022 | $273.7M |
| 2023 | $366.4M |
How accurately did Axonics Modulation Technologies' revenue projections match actual performance?
Axonics Modulation Technologies annual growth
Axonics Modulation Technologies saw the greatest revenue growth in 2019, when revenue increased by 1,854.74%.
Axonics Modulation Technologies had the lowest revenue growth in 2022, when revenue changed by 51.81%.
Axonics Modulation Technologies annual growth rate over time
| Year | Axonics Modulation Technologies growth |
|---|---|
| 2018 | 452%↑ |
| 2019 | 1855%↑ |
| 2020 | 707%↑ |
| 2021 | 62%↑ |
| 2022 | 52%↑ |
| 2023 | 34%↑ |
Axonics Modulation Technologies quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
Axonics Modulation Technologies quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2018 | - | - | $201,000 | $494,000 |
| 2019 | $1.1M | $1.5M | $1.3M | $9.9M |
| 2020 | $26.3M | $15.2M | $35.2M | $34.8M |
| 2021 | $34.4M | $45.9M | $46.9M | $53.1M |
| 2022 | $48.4M | $69.0M | $70.4M | $85.9M |
| 2023 | $70.7M | $92.9M | $93.1M | $109.7M |
| 2024 | $91.4M | $114.6M | $116.2M | - |
Axonics Modulation Technologies jobs nearby
Do you work at Axonics Modulation Technologies?
Is Axonics Modulation Technologies transparent about its revenue structure?
Axonics Modulation Technologies financial information
| CEO | Raymond Wayne Cohen |
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 416 |
| Date Founded | 2013 |
| Headquarters | Irvine, California |
| Number of Locations | 1 |
| Revenue | $366.4M |
| Net Income | -$59,698,000 |
| Gross Proft | $274.6M (2023) |
| EBITDA | ($17.0M) (2023) |
| Tax Rate | 0.3% |
| Total Assets | $659,353,000 |
| Ticker | AXNX |
Axonics Modulation Technologies jobs you might like
Axonics Modulation Technologies financing
Axonics Modulation Technologies received early financing of $32.6M on 2014-03-25.
| Series | Round size | Date |
|---|---|---|
| Series A | $32.6M | 03/2014 |
| Series B | $38.5M | 12/2015 |
| Series C | $14.5M | 05/2017 |
| Series C | $20.5M | 07/2017 |
| Series C | $40M | 04/2018 |
| Post Ipo Equity | $110M | 11/2019 |
| Post Ipo Equity | $17M | 12/2019 |
| Post Ipo Equity | $149.5M | 05/2020 |
| Post Ipo Equity | $201.3M | 05/2021 |
Axonics Modulation Technologies investors
| Investors | Security type |
|---|---|
| ANDERA PARTNERS | Series A |
| NEOMED MANAGEMENT AS | Series A |
| Legend Capital | Series A |
| Aperture Venture Partners | Series A |
| ANDERA PARTNERS | Series B |
| Cormorant Asset Management | Series B |
| NEOMED MANAGEMENT AS | Series B |
| Legend Capital | Series B |
| Advent Life Sciences LLP | Series B |
| ANDERA PARTNERS | Series C |
| Cormorant Asset Management | Series C |
| NEOMED MANAGEMENT AS | Series C |
| Legend Capital | Series C |
| Advent Life Sciences LLP | Series C |
| Cormorant Asset Management | Series C |
| Gilde Healthcare | Series C |
| Longitude Capital | Series C |
| SVB Financial Group | Series C |
| Gilde Healthcare | Series C |
Axonics Modulation Technologies revenue FAQs
Search for jobs
Axonics Modulation Technologies highest paying jobs
Zippia gives an in-depth look into the details of Axonics Modulation Technologies, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Axonics Modulation Technologies. The employee data is based on information from people who have self-reported their past or current employments at Axonics Modulation Technologies. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Axonics Modulation Technologies. The data presented on this page does not represent the view of Axonics Modulation Technologies and its employees or that of Zippia.
Axonics Modulation Technologies may also be known as or be related to AXONICS, INC., Axonics Modulation Technologies, Axonics Modulation Technologies Inc, Axonics Modulation Technologies Inc. and Axonics Modulation Technologies, Inc.